Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 3(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06996951Phase 3Recruiting

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

Role: collaborator

NCT01408732Phase 1Completed

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

Role: collaborator

NCT01197612Phase 3Completed

Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis

Role: collaborator

All 3 trials loaded